Published on January 11, 2007
PRESS
RELEASE
FOR
IMMEDIATE RELEASE
East
Setauket, New York, January 11, 2007—Lixte Biotechnology Holdings, Inc.
announced today that its wholly owned subsidiary, Lixte Biotechnology, Inc.
entered into an agreement with the Institute of Pathology at the University
of
Regensburg in Germany to obtain a supply of high quality, accurately annotated
tissue and blood samples for cancers other than brain cancers. This arrangement
provides Lixte with appropriate clinical samples for which permission has been
obtained to study any molecular feature of the tissue for commercial
purposes.
Clinical
samples will be obtained from patients who have given their signed informed
consent by persons identified by the University of Regensburg, Germany. These
are employees of the University who have approval by the University to seek
such
permission under a consent form approved by the University. The scope of use
has
been narrowed to the study of human cancers for the purpose of developing
improved methods of diagnosis, estimation of prognosis, treatment and
understanding causation of human cancers.
About
Lixte Biotechnology Holdings, Inc.
Lixte
was
organized to capitalize on opportunities for the company to develop low cost,
specific, and sensitive tests for the early detection of cancers to better
estimate prognosis, to monitor treatment response, and to reveal targets for
development of more effective treatments. Lixte is concentrating on discovering
biomarkers for common cancers for which better diagnostic and therapeutic
measures are needed. For each of these diseases a biomarker that would enable
identification of the presence of cancer at a stage curable by surgery could
possibly save thousands of lives annually. In addition, biomarkers specific
to
these diseases may also provide clues as to processes (biological pathways)
that
characterize specific cancer types and that may be vulnerable to drug treatment
targeted to the activity of the biomarker.
The
Company, from time to time, may discuss forward-looking information. Except
for
the historical information contained in this release, all forward-looking
statements are predictions by the Company’s management and are subject to
various risks and uncertainties that may cause results to differ from
management’s current expectations. Such factors include the fact that the
Company is engaged in early stage research and does not expect to obtain any
revenues for several years and other risks as detailed from time to time in
the
Company’s registration statement and reports and filings with the Securities and
Exchange Commission. All forward-looking statements, if any, in this release
represent the Company’s judgment as of the date of this release. The Company
disclaims, however, any intent or obligation to update forward-looking
statements.
|
CONTACT:
|
Lixte
Biotechnology Holdings, Inc.
|
|
Jane
Trigg
|
|
|
Telephone:
(631) 830 7092
|
|
|
Email:
jtrigg@lixte.com
|